Amlodipine plus Botulinum toxin
Phase 2Small molecule
Amlodipine plus Botulinum toxin is one of 6 small molecule programs targeting Focal Dystonia. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Focal Dystonia
#DrugCompanyPhaseTrials
1Mexitil
Boehringer IngelheimPhase 2
Ambien
PPurdue Pharma LP
Phase 1
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Amlodipine plus Botulinum toxin
NNational Institute of Neurological Disorders and Stroke (NINDS)
Phase 2
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Focal Dystonia1 trial
Amlodipine Plus Botulinum Toxin for Focal Dystonia
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00015457·16 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details